Real-World check: arthritis drug xeljanz XR under safety watch in korea

This study is a post-marketing surveillance required by Korean regulators to monitor the safety and effectiveness of Xeljanz XR (tofacitinib) in everyday medical practice. It will enroll about 200 adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who are already prescribed the drug. Researchers will track side effects and disease activity scores over roughly four years. The goal is to confirm the drug's real-world safety profile and how well it controls arthritis symptoms.